2021
DOI: 10.1016/s2352-3018(21)00103-x
|View full text |Cite
|
Sign up to set email alerts
|

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Abstract: Background Data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40 million people globally living with HIV who might have less functional immunity and more associated comorbidities than the general population. We aimed to explore safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV. Methods In this single-arm open-label vaccination substudy within the protocol of the larger phase 2/3 trial COV002, adults aged 18–55 years … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

24
199
5
2

Year Published

2021
2021
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 205 publications
(233 citation statements)
references
References 31 publications
24
199
5
2
Order By: Relevance
“…The vast majority of included studies evaluated vaccines developed by Pfizer (BNT162b2) or Moderna (mRNA-1273). Thirteen studies included patients who received the vaccine developed by Janssen (Ad26.COV2.S) [ [25] , [26] , [27] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] ], nine included patients vaccinated with the AstraZeneca vaccine (ChAdOx1) [ [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] ], three included patients receiving the CoronaVac vaccine (Sinovac Biotech) [ [50] , [51] , [52] ], and one randomized controlled trial evaluated the vaccine developed by Novavax (NVX-CoV2373) vaccine [ 53 ]. One study included patients receiving the BBV152-Covaxin (Bharat Biotech) vaccine [ 44 ] and one included patients receiving the BBIBP-CorV (Sinopharm) vaccine [ 54 ].…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…The vast majority of included studies evaluated vaccines developed by Pfizer (BNT162b2) or Moderna (mRNA-1273). Thirteen studies included patients who received the vaccine developed by Janssen (Ad26.COV2.S) [ [25] , [26] , [27] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] ], nine included patients vaccinated with the AstraZeneca vaccine (ChAdOx1) [ [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] ], three included patients receiving the CoronaVac vaccine (Sinovac Biotech) [ [50] , [51] , [52] ], and one randomized controlled trial evaluated the vaccine developed by Novavax (NVX-CoV2373) vaccine [ 53 ]. One study included patients receiving the BBV152-Covaxin (Bharat Biotech) vaccine [ 44 ] and one included patients receiving the BBIBP-CorV (Sinopharm) vaccine [ 54 ].…”
Section: Resultsmentioning
confidence: 99%
“…Most studies assessed anti-SARS-CoV-2 immunity through an immunoassay to detect antibodies targeted at the spike protein, including some targeting specifically the receptor-binding domain (RBD) of the spike protein. Thirty studies reported neutralization assay results in addition to anti-SARS-CoV-2 antibody assays [ 34 , 37 , 41 , 48 , 51 , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] ]. Thirty-one studies provided data on cellular immunity [ 17 , 21 , 22 , 34 , 37 , 41 , 45 , 46 , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , 72 , [74] , [75] , [76] , [77] , [79] , [80] , [81] , [82] , [83] , [84] ].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…As a consequence, PLWH were prioritized to receiving anti-SARS-CoV-2 vaccines in many countries. However, while data on the effects of SARS-CoV-2 vaccines in PLWH is increasing, it is still sparse [ 9 , 10 ]. It has been demonstrated before that (for some vaccines) the degree of protection and/or the humoral response in PLWH (children and adults) differs from the one observed in a general population [ 11 , 12 ].…”
Section: Introductionmentioning
confidence: 99%
“…So far, 4 different types of COVID-19 vaccines have been introduced to immunize individuals as following: 1) SARS-CoV-2 viral (inactivated) vaccine uses the whole virus to immunize individual after a certain process to kill virus preventing infection ( 30 ); 2) SARS-CoV-2 mRNA vaccine is to deliver the whole codon of S gene mRNA into a cell to express spike protein. The vaccinated individuals generate Abs against foreign spike Ag that eventually protect the individual from SARS-CoV-2 viral infection ( 31 ); 3) SARS-CoV-2 adenovirus vector vaccine is to use adenovirus to deliver the whole codon of S gene into a cell to express spike protein and the mechanism is similar to mRNA vaccine ( 32 33 34 ); 4) SARS-CoV-2 protein vaccine is to use recombinant spike protein prepared using expression systems in various cells, recently insect cells were used to ensure the native conformation expression to immunize individual, which generates Abs against spike protein to protect individual ( 35 36 37 ). The ultimate goal of the COVID-19 vaccine is to generate neutralizing Abs to protect an individual from SARS-CoV-2 viral infection as well as to prevent the spread of SARS-CoV-2 through some differences in method to generate Abs.…”
Section: Introductionmentioning
confidence: 99%